Skip to Main Content

Spotlight on... awareness weeks

Awareness weeks guide

Cervical Cancer Awareness Week

Cervical Cancer Awareness Week

10-16 November 2024

This year’s theme is The Power of choice.  You can choose to protect yourself from cervical cancer with more choice than ever before. With changes to our National Awareness and Screening programs, preventing cervical cancer has never been easier. Australian Cervical Cancer Awareness Foundation

UpToDate

Diagnosis

General

Screening

Treatment

Cochrane Library

Guidelines

Online resources

Reports

Articles

Prevention

Screening

Research

Treatment

E-books

E-journals

__________________________________________________________________________________

Articles

Prevention

The AOFOG recommendations on human papillomavirus vaccination in the Asia-Pacific region
The Asia and Oceania Federation of Obstetrics and Gynecology envisages a need to produce a set of recommendations on the implementation of human papilloma virus vaccination program for both lower-middle-income countries (LMICs) and high-income countries (HICs), with an attempt to harmonize the practices yet allow flexibility to cater for different cultures, religions, needs and background of individual countries/cities. The journal of obstetrics and gynaecology research 29 October 2024

Coverage of cervical cancer prevention interventions among people in Australia who inject drugs
Highlights

  • Cervical screening coverage was similar to the Australian general population.
  • Awareness of self-sampling availability for cervical screening was low.
  • Human papillomavirus vaccination coverage was 38 % lower than the general population.

International journal of drug policy 21 August 2024

Asia Oceania Federation of Obstetrics and Gynecology (AOFOG)'s efforts in the cervical cancer elimination program in the Asia-Pacific
AOFOG supports member countries through initiatives such as educational campaigns, guidelines development, and collaboration with local and international partners. Variations in screening methods across AOFOG member countries reflect diverse socioeconomic contexts and healthcare infrastructures, ranging from HPV testing in countries like Australia and Malaysia to cytology and visual inspection methods in others. Innovations such as HPV self-testing and AI-enhanced screening are emerging to improve accessibility and accuracy, addressing barriers like stigma and resource scarcity. Despite challenges, AOFOG remains committed to reducing cervical cancer incidence and mortality through coordinated regional efforts, aiming for equitable access to preventive measures and treatment across the diverse landscape of the Asia-Pacific region. The journal of obstetrics and gynaecology research 29 October 2024

Opportunities to advance cervical cancer prevention and care
This review discusses ways that recent technological advancements could be leveraged to improve CaCx care and prevention. Tumour virus research 25 October 2024

Addressing the global challenge: Strategies for Cervical prevention and early detection within WHO's 90-70-90 Framework
Cervical cancer represents a substantial global health issue, standing as the third most prevalent cancer globally and the principal cause of cancer-associated mortality in women, with an uneven burden shouldered by less developed countries. Despite being the most preventable malignancy, with nearly all cases attributed to HPV infection, which has a lifetime cumulative risk of 80% through sexual transmission, cervical cancer remains a pressing issue. National cervical cytology screening programs have been implemented to identify cervical abnormalities, lesions, and early malignancies in eligible women. However, the utilization of screening techniques is declining, and due to resource constraints, screening schemes have not been adopted in less-developed economies. Several nations have embraced alternative screening techniques, such as Visual Inspection with Acetic Acid (VIA), which have shown impacts on mortality and morbidity rates. With the rising accessibility of efficacious HPV screening and self-testing, there will be a necessity to reconfigure existing cervical screening programs. Furthermore, preventative HPV vaccination is an integral part of the World Health Organization’s (WHO) Global Strategy to Expedite the Eradication of Cervical Cancer as a Public Health Issue, necessitating the restructuring of vaccination endeavors. This review article evaluates potential techniques for detecting precancerous lesions within the context of the WHO's 90-70-90 global policy for cervical cancer prevention and early diagnosis. The incidence and mortality rates are examined, highlighting the effectiveness of cervical cancer prevention efforts. The Journal of Phytopharmacology 30 July 2024

__________________________________________________________________________________

Research

Impact of human papillomavirus types on uterine cervical neoplasia
this review outlines the natural history of HPV-infected cervical lesions and the characteristics of each HPV genotype. The journal of obstetrics and gynaecology research 9 June 2024

HPV and cervical cancer awareness and screening practices among migrant women: A narrative review
This narrative review explores the barriers and facilitators that migrant women face globally. The review explored a range of studies conducted in various countries, including the United States of America (USA), the United Kingdom (UK), Canada, Australia, and the United Arab Emirates (UAE). Healthcare 21 March 2024

Intraoperative radiation therapy for recurrent cervical and endometrial cancer: Predicting morbidity and mortality in a contemporary cohort
Intraoperative radiation therapy (IORT) can be a useful treatment modality in patients with recurrent cervical or endometrial cancer. The existing literature on IORT use in recurrent gynecologic malignancies is limited by small sample sizes because few centers use IORT and few patients are ideal candidates. The aim of this study is to describe a modern cohort of patients who were considered for IORT and predict risk factors of morbidity and mortality. The authors found that appreciable survival gain can be achieved with the use of IORT, with factors such as ECOG performance status (ECOG PS), neoadjuvant chemotherapy/immunotherapy, pelvic sidewall involvement, whether exenteration was performed, and resection margin status influencing the risk of morbidity and/or mortality. Cancers 28 October 2024

_________________________________________________________________________________

Screening

Correlates of intention-to-attend and confirmed cervical screening attendance during the COVID-19 pandemic in Australia: Findings from Compass-PLUS, a prospective cohort study
Highlights

  • Little is known on factors affecting screening intention/attendance during COVID.
  • Intention-to-screen was related to family cancer history and non-urban living.
  • Age, employment status, and screening history influenced cervical screening.
  • Screening de-prioritisation and recent anxiety was linked to lower attendance.
  • Cervical screening attendance differed between younger and older women.

Preventative medicine reports 5 August 2024

What young women (aged 24–29 years) in Australia think about self-collection for cervical screening: a brief report
Self-collection is a valuable addition to the National Cervical Screening Program. This study suggests that continued efforts are needed to raise awareness of its availability, and improve understanding about its accuracy, the ease of collection, that you still need to engage with a primary healthcare service to access it and that you can still opt for a clinician-collected test. Sexual health 4 June 2024

Providing a localised cervical cancer screening course for general practice nurses
Cervical cancer screening programs in Australia have been developed to detect early precancerous changes in women with a cervix aged between 25 and 74. Yet, many barriers remain to the uptake of cervical screening. The aim of this paper is to generate further discussion on the need for training programs to be made available in rural and remote areas to aid the upskilling of General practice nurses (GPNs). Australian journal of primary health 2 September 2024

Inclusive language in health policy – a timely case (study) of cervical screening in Australia
Language is important in health policy development. Policy changes in Australia to increase cervical screening offers a timely case example to explore the function of inclusive language in health policy. Gender and sexuality diverse people with a cervix have been largely invisible within health promotion programs, which has led to reduced awareness of, and access to, cervical screening. Health sociology review 5 June 2024

Practitioners support and intention to adopt universal access to self-collection in Australia's National Cervical Screening Program
The extent to which self-collection can promote equity within the program will be limited without wide-spread adoption by practitioners. Communication and education that addresses concerns of practitioners, along with targeted implementation support, will be critical to ensuring that self-collection can increase participation and Australia's progression towards elimination of cervical cancer. Cancer medicine 24 May 2024

The future of Cervical Cancer screening
Screening for human papillomavirus (HPV) and cervical dysplasia (CD) plays a pivotal role in reducing the risk of cervical cancer-related mortality. The development of novel technologies, along with efforts to enhance global health equity and integrate cervical cancer prevention with HIV screening and treatment programs, represent critical steps toward achieving comprehensive cervical cancer screening on a global scale. International journal of women’s health 22 October 2024

_______________________________________________________________________________

Treatment

The current state and future perspectives of radiotherapy for cervical cancer
This review provides an overview of technological innovations and future perspectives in radiotherapy for cervical cancer. The journal of obstetrics and gynaecology research 17 June 2024

Fertility-sparing surgery and fertility preservation in cervical cancer: The desire for parenthood, reproductive and obstetric outcomes
Highlights

  • The majority of cervical cancer survivors desiring fertility-sparing treatment, maintain their desire for parenthood after cancer treatment.
  • For patients with early-stage disease, vaginal radical trachelectomy shows good reproductive outcomes.
  • For patients requiring (chemo)radiotherapy, fertility preservation is successful in the majority of patients.
  • Gestational surrogacy with frozen-thawed material enables those without a (functional) uterus to have a genetic offspring.

Gynecologic oncology 20 December 2021

Standard of care treatment for stage IVB cervical cancer: A systematic review and meta-analysis
Highlights

  • Stage IVB cervical cancer (CC) is studied with persistent and recurrent CC, but has poorer survival outcomes.
  • Standard of care for advanced CC is combination chemotherapy.
  • Trials are likely to lead to changes in the standard of care.
  • Improving outcomes for the highest risk group, stage IVB CC, will continue to be important.

Gynecologic oncology 30 October 2024

Comparative analysis of digital transcriptomics between pre- and post-treatment samples of patients with locally advanced cervical cancer: A preliminary study
This study provides new insights into the molecular mechanisms underlying treatment response and resistance. Current issues in molecular biology 28 October 2024

Latest findings in chemotherapy
Radiotherapy and surgery are the two pivotal curative treatments for cervical cancer. Although cervical cancer is relatively sensitive to chemotherapy, chemotherapy is not included in the curative treatment of cervical cancer and has a role in limited medical conditions. Chemotherapy used to treat cervical cancer can be divided into four categories: (1) preceding chemotherapy (neoadjuvant chemotherapy) to augment the effects of radical therapy (surgery or radiation therapy), (2) chemotherapy administered concurrently with radiation therapy, and (3) adjuvant chemotherapy administered after radical therapy. In addition, (4) chemotherapy is used to prolong survival and alleviate symptoms in patients who cannot be radically cured. Recently, molecular targeted agents, angiogenesis inhibitors, and immune checkpoint inhibitors have been incorporated into existing chemotherapy regimens. This review summarizes these trends along with the history of chemotherapy for cervical cancer. Journal of obstetrics and gynaecology research 29 October 2024

__________________________________________________________________________________

E-books

This is just a sample of the e-books the library subscribes to – you will need your library login

__________________________________________________________________________________

E-Journals

A sample of the journals the library subscribes to – you will need your library login

__________________________________________________________________________________